术者主导的前列腺癌淋巴结分期:机器人辅助不同清扫模板与患者选择下的病理结局
该单中心回顾性研究分析2006-2012年三种盆腔淋巴结清扫策略下机器人辅助根治性前列腺切除术的围手术期、病理和肿瘤学结局。扩大盆腔淋巴结清扫显著提高淋巴结检出数和阳性率,对高危患者影响最大,但手术时间约延长一倍且并发症无显著差异;遗漏清扫导致16-19%的pNx后悔率。
要点
- 扩大盆腔淋巴结清扫显著提高淋巴结检出数(14-20枚)和阳性率(17.4-18.4%),对高危患者影响最大。
- 遗漏清扫导致16-19%的pNx后悔率,且单侧病变阳性淋巴结患者中三分之一存在对侧病变。
- 扩大清扫手术时间约延长一倍,但并发症无显著差异(5.0% vs 6.0%,P=0.511)。
核心结论
- 扩大盆腔淋巴结清扫的净获益仍不确定,鉴于强选择标准,其治疗影响可能需要随机试验验证。
- 扩大清扫有助于显著数量高危和中危患者的肿瘤学分期,且应行双侧清扫。
研究设计与样本
- 2006-2012年单中心癌症转诊医院6年间按时间顺序采用三种盆腔淋巴结清扫策略的回顾性队列研究。
- 策略一(2006年4月-2007年10月):主导Gleason评分4-5或PSA>10 ng/mL者行标准模板清扫,否则省略清扫。
- 策略二(2007年11月-2010年12月):主导Gleason评分4-5、PSA>10 ng/mL、任一单针>7 mm或同侧>3针阳性者行扩大模板清扫,否则省略或标准清扫。
- 策略三(2011年1月-2012年8月):几乎无例外行扩大模板清扫。
主要发现
- 标准盆腔淋巴结清扫检出8-10枚淋巴结,阳性率为2.2-6.2%。
- 扩大盆腔淋巴结清扫显著提高淋巴结检出数至14-20枚,阳性率至17.4-18.4%(均P<0.001)。
- 扩大清扫对高危疾病阳性淋巴结百分比影响最大(9.3% vs 32.8%,P=0.002),中危影响中等(4.2% vs 10.9%,P=0.003),低危影响极小(4.1% vs 0%,P=0.401)。
- 极低阈值扩大清扫联合分袋送检增加淋巴结检出数(18 vs 24,P<0.001),但未显著改变各临床风险组的阳性淋巴结百分比(P=0.975)。
- 单侧病变且淋巴结阳性患者中三分之一发现对侧病变;活检体积最小的Gleason 4+3患者扩大清扫后pN1率为3/14(21%),而Gleason 3+4者为0/31。
关键数值与推荐
- 扩大盆腔淋巴结清扫手术时间约为标准清扫的两倍,但并发症无统计学显著差异(5.0% vs 6.0%,P=0.511)。
- 基于临床标准省略扩大清扫导致16-19%的pNx后悔率。
- 5年生化复发率因选择标准在扩大清扫组更高,但总生存无差异。
临床怎么用
- 对高危和中危前列腺癌患者应考虑行双侧扩大盆腔淋巴结清扫以改善肿瘤学分期。
- 基于临床标准省略扩大清扫需谨慎,因存在16-19%的pNx后悔率。
- 单侧病变患者仍应行双侧清扫,因三分之一存在对侧淋巴结转移。
局限性
- 单中心回顾性研究,三种策略按时间顺序实施,存在选择偏倚。
- 扩大清扫的净获益不确定,治疗影响需随机试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the perioperative, pathological, and oncological outcomes from surgeon-led pathological staging of pelvic lymph node (LN) metastases at the time of robot-assisted radical prostatectomy (RARP). PATIENTS AND METHODS: Over the 6-year period of 2006-2012, three distinct pelvic LN dissection (PLND) strategies were used in chronological order at a single cancer referral hospital. Strategies were characterised by both an omission of PLND (pNx) vs inclusion decision threshold, and standard vs extended templates for patients selected for PLND. The three cohorts included: (i) omission vs standard template (04/2006-10/2007), for dominant Gleason score 4-5 or a prostate-specific antigen (PSA) level of >10 ng/mL; (ii) omission/standard vs extended template (11/2007-12/2010), for dominant Gleason score 4-5, PSA level of >10 ng/mL, any single core >7 mm, or >3 ipsilateral positive cores; and (iii) extended template with minimal exceptions (01/2011-08/2012). Standard outcomes data compared included: Clavien-Dindo complication rates, LN metrics (yield, percentage positive), and biochemical recurrence (BCR). A novel metric comprised 'pNx regret': the rate of pNx patients upgraded/upstaged. Exploratory analyses included selection criteria for reduced PLND templates, i.e. low-yield subsets. RESULTS: Standard PLND yielded 8-10 LNs and a positive-LN yield of 2.2-6.2%. The addition of an extended PLND (E-PLND) significantly increased the yield to 14-20 LNs and the positive-LN yield to 17.4-18.4% (both P < 0.001). E-PLND had the highest impact on the percentage of positive LNs (%pN1) for high-risk disease (9.3 vs 32.8%, P = 0.002), modest for intermediate risk (4.2 vs 10.9%, P = 0.003), and minimal impact on low risk disease (4.1 vs 0%, P = 0.401). The combined strategies of setting a very low threshold for E-PLND and sending separate LN packets increased the LN yields (18 vs 24, P < 0.001), but did not significantly change the observed %pN1 rates by clinical risk group (P = 0.975). Efforts to reduce the need for E-PLND included omission by clinical criteria, but resulting in 'pNx regret' in 16-19%. A third of patients with unilateral disease and positive LNs were found to have contralateral disease. A subset of men with minimal biopsy volume Gleason score 4 + 3 had pN1 rates after E-PLND of three of 14 (21%) compared to minimal biopsy volume Gleason score 3 + 4 pN1 rates after E-PLND of 0 of 31. E-PLND takes about twice as long to perform but with no statistically significant difference in complications (5.0 vs 6.0%, P = 0.511). The 5-year BCR rates were higher for E-PLND, given the selection criteria, but not different for overall survival. CONCLUSIONS: The net benefit of E-PLND remains uncertain, and therapeutic impact will probably require a randomised trial, given the strong selection criteria. E-PLND contributes to oncological staging in a significant number of high- and intermediate-risk patients, and should be bilateral. Immediate concerns include longer operative times, but no higher complication rates.
引用
- Altok M, Babaian K, Achim MF, et al. Surgeon-led prostate cancer lymph node staging: pathological outcomes stratified by robot-assisted dissection templates and patient selection. BJU Int. 2018. PMID: 29446205. doi:10.1111/bju.14164
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。